Latest News On Cancer

Latest California Healthline Stories

Scientists Say NIH Officials Told Them To Scrub mRNA References on Grants

Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.

Future of Cancer Coverage for Women Federal Firefighters Uncertain Under Trump

In the waning days of the Biden administration, the Labor Department added ovarian, uterine, cervical, and breast cancer coverage for wildland firefighters. It’s unclear whether the new protections will stick under Trump.

KFF Health News' 'What the Health?': New Year, New Congress, New Health Agenda

Health is unlikely to be a top priority for the new GOP-led 119th Congress and President-elect Donald Trump. But it’s likely to play a key supporting role, with an abortion bill already scheduled for debate in the Senate. Meanwhile, it’s unclear when and how the new Congress will deal with the bipartisan bills jettisoned from the previous Congress’ year-end omnibus measure — including a major deal to rein in the power of pharmacy benefit managers. In this “catch up on all the news you missed” episode, Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.

Traveling To Die: The Latest Form of Medical Tourism

Medical aid in death is legal in 10 states and the District of Columbia. But only Oregon and Vermont explicitly allow out-of-state people who are terminally ill to die with assistance there. So far, at least 49 people have made the trek while state legislation stalls elsewhere.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care

For rural patients, getting cancer treatment close to home has always been difficult. And now chemotherapy deserts are expanding across the United States as hospitals winnow services to save money, creating financial and logistical hurdles for people seeking lifesaving care.

Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.